3,6-Dihydroxyxanthone
目录号 : GC66212
3,6-Dihydroxyxanthone (compound 3) 是黄酮衍生物。3,6-Dihydroxyxanthone (compound 3) 具有抗癌活性。3,6-Dihydroxyxanthone (compound 3) 可用于癌症研究。
Cas No.:1214-24-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
3,6-Dihydroxyxanthone (compound 3) is a xanthone derivatives. 3,6-Dihydroxyxanthone (compound 3) has anticancer activity. 3,6-Dihydroxyxanthone (compound 3) can be used for cancer research[1].
3,6-Dihydroxyxanthone (compound 3) (3.906-1000 µg/mL; 24 hours) exhibits cytotoxic activity against WiDR and Vero cell lines with IC50 values of 785.58 and 1280.9 µM[1].
Cell Cytotoxicity Assay[1]
| Cell Line: | WiDR and Vero cell lines |
| Concentration: | 3.906, 7.813, 15.625, 31.25, 62.5, 125, 250 and 500 µg/mL (WiDR cell line)7.813, 15.625, 31.25, 62.5, 125, 250, 500 and 1000 µg/mL (Vero cell line) |
| Incubation Time: | 24 hours |
| Result: | Inhibited cell activity and with IC50 values of 785.58 and 1,280.9 µM for WiDR and Vero cell lines. |
| Cas No. | 1214-24-0 | SDF | Download SDF |
| 分子式 | C13H8O4 | 分子量 | 228.2 |
| 溶解度 | 储存条件 | 4°C, stored under nitrogen | |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 4.3821 mL | 21.9106 mL | 43.8212 mL |
| 5 mM | 0.8764 mL | 4.3821 mL | 8.7642 mL |
| 10 mM | 0.4382 mL | 2.1911 mL | 4.3821 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
gamma-Pyrone compounds. IV: Synthesis and antiplatelet effects of mono- and dioxygenated xanthones and xanthonoxypropanolamine
J Pharm Sci 1993 Jan;82(1):11-6.PMID:8429484DOI:10.1002/jps.2600820103.
Xanthodilol, mono- and dioxygenated xanthones, and 1,3-, 2,3-, 3,4-, 3,5-, 1,6-, 2,6- and 3,6-dioxygenated xanthones were synthesized from benzophenone precursors by Friedel-Crafts acylation and subsequent base-catalyzed cyclization to eliminate methanol. 3-Hydroxy-xanthone, xanthodilol, 2,3-dihydroxyxanthone diacetate, and 3,4-dihydroxyxanthone and its diacetate showed potent antiplatelet effects on arachidonate- and collagen-induced aggregation. 3,5-Dihydroxyxanthone and its diacetate, 1,6-dimethoxyxanthone, and 3,6-Dihydroxyxanthone and its diacetate showed potent antiplatelet effects on arachidonate-induced aggregation.